Kratom Use and Toxicities in the United States
@article{Eggleston2019KratomUA, title={Kratom Use and Toxicities in the United States}, author={William Eggleston and Robert Stoppacher and Kyle Suen and Jeanna M Marraffa and Lewis S. Nelson}, journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy}, year={2019}, volume={39} }
Kratom is an herbal supplement containing alkaloids with opioid properties. This review was conducted to determine toxicities associated with kratom use in the United States in order to provide insight into its safety as a dietary supplement.
33 Citations
Kratom exposures among older adults reported to U.S. poison centers, 2014–2019
- MedicineJournal of the American Geriatrics Society
- 2021
Healthcare providers and older adult patients should be aware of the potential risks of kratom use, including medication interactions and falls, when reviewing medication lists and query this population for all medications and substances being used.
Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review
- MedicinePain and Therapy
- 2020
This manuscript will discuss the most current epidemiology, pharmacology, toxicity, and management related to kratom, while seeking to provide a contemporary perspective on the issue and its role in the greater context of the opioid epidemic.
Kratom (Mitragyna speciosa)-Induced Hepatitis
- MedicineACG case reports journal
- 2022
A case report is provided detailing the clinicopathologic findings of drug-induced liver injury caused by kratom, and Liver biopsy demonstrated a prominent canalicular cholestatic pattern, mixed portal inflammation, and newly described perivenular necrosis.
Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States
- MedicineFrontiers in Pharmacology
- 2021
This report highlights how converging factors have led to a surge in interest in kratom as a potential harm reduction agent in the treatment of pain and opioid use disorder.
Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa)
- Biology, MedicineJournal of clinical pharmacology
- 2021
Until studies are conducted that define kratom's role in treating opioid withdrawal and/or other central nervous system conditions, kratom will likely remain available as a dietary supplement for the foreseeable future.
Pharmacologic and clinical assessment of kratom: An update.
- MedicineAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
- 2019
Kratom has a unique pharmacologic profile that might offer advantages over other opioids, but its high abuse liability, potential for drug interactions and adverse events, and inadequate research into the balance of benefits to harm are concerning.
Kratom
- BiologyCanadian Medical Association Journal
- 2019
Kratom is a herbal product that is most commonly obtained as a powder and consumed as a beverage that reduces pain, cause dose-dependent stimulant and sedative effects, and have an adverse effect profile consistent with opioids.
Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant
- BiologyFrontiers in Psychiatry
- 2021
The case of a patient who developed anxiety and dysphoric mood and insomnia while using kratom, with these symptoms persisting after withdrawal, is described.
Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
- MedicineJournal of ethnopharmacology
- 2019
References
SHOWING 1-9 OF 9 REFERENCES
The pharmacology and toxicology of kratom: from traditional herb to drug of abuse
- MedicineInternational Journal of Legal Medicine
- 2015
There are currently no standard analytical screening techniques for mitragynine and its metabolites following ingestion limiting its detection to more sophisticated techniques like liquid chromatography-mass spectrometry to determine kratom use.
Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth).
- MedicineAddiction
- 2008
The predominant alkaloid of kratom, mitragynine, binds mu- and kappa-opioid receptors, but has additional receptor affinities that might augment its effectiveness at mitigating opioid withdrawal.
Pharmacokinetics of mitragynine in man
- Medicine, BiologyDrug design, development and therapy
- 2015
The first pharmacokinetic study in humans, which demonstrated linearity and was consistent with the oral two-compartment model with a terminal half-life of about 1 day, suggests there is a possibility for it to be developed medically as a pain killer or better opioid substitute in the future.
Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine
- BiologyJournal of Medical Toxicology
- 2016
A unique form of product adulteration is described, which stresses the importance of increased dietary supplement oversight of Kratom-containing supplements.
Discriminative stimulus properties of mitragynine (kratom) in rats
- Biology, PsychologyPsychopharmacology
- 2015
It is demonstrated that the discriminative stimulus effect of MG possesses both opioid- and psychostimulant-like subjective effects.
Patterns of Kratom use and health impact in the US-Results from an online survey.
- MedicineDrug and alcohol dependence
- 2017
Dietary supplements: how they are used and regulated.
- MedicineThe Journal of nutrition
- 2001
Overall use of nutrient and botanical dietary supplements (DS) has increased for years across all major categories, but the wording of S/F claims has become a difficult issue in the proposed DS labeling regulations.
Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.
- MedicineDrug and alcohol dependence
- 2017
HHS recommended that the DEA ban kratom, documents show